To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective
Department of Medical Science, Section of Hematology, Uppsala University, Uppsala, Sweden.
Section of Hematology and Coagulation, Department of Specialist Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Hematology, Linköping University Hospital, Linköping, Sweden.
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Show others and affiliations
2023 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 37, no 5, p. 1103-1112Article in journal (Refereed) Published
Abstract [en]

In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications of type of previous treatment and primary disease. We combined data from MDS patients, diagnosed between 2009 and 2017 (n = 2705), in the nationwide Swedish MDS register, with several health registers. Furthermore, using matched population controls, we investigated the prevalence of antecedent malignancies in MDS patients in comparison with the general population. This first ever nationwide study on t-MDS confirms a shorter median survival for t-MDS compared to de novo MDS (15.8 months vs 31.1 months, p < 0.001). T-MDS patients previously treated with radiation only had disease characteristics with a striking resemblance to de novo-MDS, in sharp contrast to patients treated with chemotherapy who had a significantly higher risk profile. IPSS-R and the WHO classification differentiated t-MDS into different risk groups. As compared with controls, MDS patients had a six-fold increased prevalence of a previous hematological malignancy but only a 34% increased prevalence of a previous solid tumor. T-MDS patients with a previous hematological malignancy had a dismal prognosis, due both to mortality related to their primary disease and to high-risk MDS.

Place, publisher, year, edition, pages
Springer, 2023. Vol. 37, no 5, p. 1103-1112
National Category
Hematology
Identifiers
URN: urn:nbn:se:oru:diva-105104DOI: 10.1038/s41375-023-01864-6ISI: 000949301500001PubMedID: 36928008Scopus ID: 2-s2.0-85150042224OAI: oai:DiVA.org:oru-105104DiVA, id: diva2:1745206
Available from: 2023-03-22 Created: 2023-03-22 Last updated: 2023-12-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Rasmussen, Bengt

Search in DiVA

By author/editor
Rasmussen, Bengt
By organisation
School of Medical Sciences
In the same journal
Leukemia
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 13 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf